Humanized Antibodies Targeting Alpha-Synuclein Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic and diagnostic approaches for neurodegenerative diseases related to α-synuclein, such as Parkinson's disease, face challenges due to the lack of specific and safe human antibodies that can effectively target toxic α-synuclein aggregates without interfering with its normal functions, and existing methods risk undesired autoimmune responses or cross-reactivity.
Innovation Solution
Development of human monoclonal antibodies and their fragments that specifically bind to epitopes within human α-synuclein, particularly targeting oligomeric or aggregated forms, with a focus on minimizing cross-reactivity and using sequences that are highly identical to natural human antibodies to reduce autoimmune risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If murine monoclonal antibodies are used to target α-synuclein aggregates, then therapeutic efficacy is improved, but human anti-mouse antibody (HAMA) response causes safety issues
Solution Approach 1:
The patent creates humanized antibodies that copy the structure and function of murine monoclonal antibodies while using human amino acid sequences. The CDR regions from the murine antibody are grafted onto human framework regions, producing an antibody that retains the ability to bind α-synuclein aggregates but is recognized as self by the human immune system, thereby eliminating the HAMA response while maintaining therapeutic efficacy.
2Ease of manufacture
If phage display library antibodies are used to target α-synuclein, then production simplicity is improved, but cross-reactivity with self-antigens increases
Solution Approach 1:
The patent modifies the amino acid sequence parameters of the antibody framework regions to match human sequences while preserving the CDR regions that provide antigen specificity. This parameter change in the framework regions reduces cross-reactivity with self-antigens while maintaining the ability to bind α-synuclein, thereby improving safety without sacrificing the production advantages of phage display technology.
3Reliability
If antibodies with high affinity for α-synuclein are developed, then neutralization of toxic aggregates is improved, but interference with normal monomeric α-synuclein function increases
Solution Approach 1:
The patent targets specific conformational epitopes on α-synuclein aggregates that are structurally distinct from the monomeric form. By designing antibodies that recognize aggregate-specific conformations through carefully selected CDR regions, the antibody achieves high affinity for toxic aggregates while maintaining selective binding that spares normal monomeric α-synuclein, thus neutralizing toxicity without interfering with physiological functions.
Data Source
AI summary
Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.